» Articles » PMID: 29063957

Significance of H3K27M Mutation with Specific Histomorphological Features and Associated Molecular Alterations in Pediatric High-grade Glial Tumors

Overview
Specialty Pediatrics
Date 2017 Oct 25
PMID 29063957
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Pediatric high-grade gliomas (pHGGs) constitute almost 15% of all childhood brain tumors. Recurrent mutations such as H3K27M mutation in H3F3A and HIST1H3B genes encoding histone H3 and its variants were identified in approximately 30% of pediatric glioblastomas. This study aimed to ascertain the morphological and molecular characteristics of pHGGs with H3K27M mutation.

Methods: In total, 61 cases of pHGGs (anaplastic astrocytoma, 12; glioblastomas, 49) from four university hospitals were studied. The histomorphological features were examined and immunohistochemistry was performed to evaluate the mutation status of H3K27M, ATRX, IDH1, BRAF V600E, and p53 genes.

Results: The study comprised 25 females and 36 males (age range, 1-18 years) with a clinical follow-up of up to 108 months. From the total, 31 patients were positive for H3K27M mutation located in the midline, mostly in the pons and thalamus. H3K27M mutation was commonly associated with ATRX loss (32.3%) and p53 (74.2%) immunoreactivity with a co-expression rate of 25.8%. While IDH1 mutation was not detected in pHGGs with H3K27M mutation, BRAFV600E mutation was rarely observed. Among the various histomorphological features, increased number of mitosis, increased Ki-67 proliferation index, and palisading and geographical necrosis along with small cell patterns were significantly associated with the H3K27M wild-type tumors. Focal infarct-like necrosis and pilomyxoid morphology was significantly associated with these tumors.

Conclusion: H3K27M mutation occurs exclusively in pHGGs arising from the midline and presents with varied histomorphological features ranging from low-grade pilomyxoid astrocytoma to highly pleomorphic glioblastoma along with ATRX loss and p53 mutations.

Citing Articles

Emerging and Biological Concepts in Pediatric High-Grade Gliomas.

Yoel A, Adjumain S, Liang Y, Daniel P, Firestein R, Tsui V Cells. 2024; 13(17.

PMID: 39273062 PMC: 11394548. DOI: 10.3390/cells13171492.


Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.

Hayashi N, Fukai J, Nakatogawa H, Kawaji H, Yoshioka E, Kodama Y Acta Neuropathol Commun. 2024; 12(1):120.

PMID: 39061104 PMC: 11282756. DOI: 10.1186/s40478-024-01808-w.


Pediatric Giant Cell Glioblastoma Presenting with Intracranial Dissemination at Diagnosis: A Case Report.

Kinoshita T, Yano H, Nakayama N, Suzui N, Iida T, Endo S NMC Case Rep J. 2022; 8(1):151-157.

PMID: 35079457 PMC: 8769385. DOI: 10.2176/nmccrj.cr.2020-0138.


MRI-based radiomics signature and clinical factor for predicting H3K27M mutation in pediatric high-grade gliomas located in the midline of the brain.

Wu C, Zheng H, Li J, Zhang Y, Duan S, Li Y Eur Radiol. 2021; 32(3):1813-1822.

PMID: 34655310 DOI: 10.1007/s00330-021-08234-9.


Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas.

Kazarian E, Marks A, Cui J, Darbinyan A, Tong E, Mueller S Sci Rep. 2021; 11(1):14377.

PMID: 34257334 PMC: 8277861. DOI: 10.1038/s41598-021-92943-0.


References
1.
Korshunov A, Schrimpf D, Ryzhova M, Sturm D, Chavez L, Hovestadt V . H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol. 2017; 134(3):507-516. DOI: 10.1007/s00401-017-1710-1. View

2.
Zhang R, Shi Z, Chen H, Chung N, Yin Z, Li K . Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget. 2015; 7(4):5030-41. PMC: 4826263. DOI: 10.18632/oncotarget.5456. View

3.
Gessi M, Gielen G, Hammes J, Dorner E, Zur Muhlen A, Waha A . H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?. J Neurooncol. 2013; 112(1):67-72. DOI: 10.1007/s11060-012-1040-z. View

4.
Pathak P, Jha P, Purkait S, Sharma V, Suri V, Sharma M . Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM. J Neurooncol. 2014; 121(3):489-97. DOI: 10.1007/s11060-014-1675-z. View

5.
Rizzo D, Ruggiero A, Martini M, Rizzo V, Maurizi P, Riccardi R . Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. Biomed Res Int. 2015; 2015:215135. PMC: 4584033. DOI: 10.1155/2015/215135. View